158 results about "Carcinoma" patented technology

Set forth are vascular valves and servovalves and methods of using the same that may be positioned in the circulatory system without interrupting blood flow to facilitate solid organ transplantation so as to reduce graft organ anoxia and degradation before and after harvesting and storage, thereby minimizing late-term cardiac allograft vasculopathy as a major cause of graft failure. Along the urinary tract, bypassing bladder-generated urge sensation by diverting urine directly from the ureters to a neobladder or collection bag alleviates intractable incontinence, nocturia, urethral syndrome, overactive bladder, dysuria, or frequency. Where the lower tract is missing, a prosthesis can thwart disease and preclude the degenerative metaplastic transition to carcinoma risked when gut is used to construct a conduit for urine, a neobladder, and / or high-maintenance stoma. Druglines to valves and servovalves can directly pipeline-target medication to nidi, anastomoses, or any other trouble spots.

The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

The invention provides an esophageal cancer marker screening method based on enzyme transfer method methylation sequencing, which comprises the following steps: S1, collecting esophageal early cancer and para-carcinoma tissue samples, and carrying out enzyme transfer method whole genome methylation sequencing; s2, integrating methylation data of esophageal cancer and para-carcinoma tissues in databases of TCGA, GEO, MethMarker DB and the like; s3, screening differential methylation sites, preferably sites which are hypermethylated in esophageal cancer but hypomethylated in samples such as leukocytes, so as to reduce plasma background interference; s4, obtaining a candidate marker combination based on an integrated methylation feature screening model of LASSO regression and a random forest algorithm; s5, constructing a classifier model based on the candidate marker combination, carrying out training and reasoning test on the model, and evaluating the prediction performance of the model; and S6, obtaining the esophageal cancer marker combination. According to the method, enzyme transfer sequencing and machine learning are combined, the marker prediction accuracy is remarkably improved, and a new reference is provided for clinical research of esophageal cancer.

The invention discloses an HLA-A * 11: 01 renal cell carcinoma tumor antigen short peptide derived from an IDO1 gene. The invention provides a tumor antigen peptide. The amino acid sequence of the tumor antigen peptide is as shown in SEQ ID No. 1. Researches find that a compound formed by the oligopeptide and a corresponding HLA molecule (HLA-A * 11: 01) can be recognized by T cells, and immune response is activated. The invention provides a potential target spot for treatment of renal cell carcinoma, and provides a new target spot screening direction for subsequent tumor antigen treatment of renal carcinoma.

The invention provides a method of treating a colorectal carcinoma with a combination of an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody. In some aspects, the combination comprises 480 mg of each antibody such as, for example, 480 mg of an anti-LAG-3 antibody (e.g, relatlimab) and 480 mg of an anti-PD-1 antibody (e.g, nivolumab). In some aspects, the colorectal carcinoma is unresectable, advanced, or metastatic, including, for example, microsatellite stable or high microsatellite instable colorectal carcinoma.

The invention discloses a hepatocellular carcinoma postoperative early recurrence prediction method based on multi-modal fusion. The method comprises the following steps: firstly, integrating clinical data of a training set, a preoperative enhanced CT image and a postoperative full-view digital pathological image, and carrying out standardized correction; then, traditional image omics features and deep learning features are extracted from the CT image, cell nucleus morphological features and tumor microenvironment spatial configuration features are extracted from the pathological image, and key feature signatures are screened out through a maximum correlation minimum redundancy algorithm (mRMR) and LASSO regression in combination with clinical features. And then carrying out progressive model construction by adopting an XGBoost algorithm, sequentially establishing a clinical single-mode model, an image single-mode model, a pathological single-mode model and a multi-mode fusion model, and explaining and visualizing the models by utilizing an SHAP value and a Grad-CAM technology. Finally, the performance of the model is evaluated in a multi-dimensional mode through internal cross validation, foresight and external independent validation, risk layering is carried out based on the prediction probability, and individualized postoperative management is guided.

The invention relates to the field of intelligent medical treatment and artificial intelligence, and discloses an AI image recognition-based antral sinus cancer accompanied pyloric obstruction preoperative precise evaluation system, which comprises a data acquisition and preprocessing module for acquiring and preprocessing structured clinical data and multi-modal image data of a patient; the focus identification and segmentation module is used for carrying out focus identification and segmentation processing on the preprocessed image data by adopting an improved nnU-Net framework; the feature extraction and screening module is used for extracting image features from the segmentation result and screening features related to clinical indexes; the multi-modal feature fusion module is used for carrying out feature fusion on the screened image features and the preprocessed structured clinical data; the multi-task risk assessment module is used for establishing a multi-parameter risk prediction model by adopting a semi-structured distribution regression method and outputting a multi-task prediction result; and the evaluation report generation module is used for generating a structured evaluation report. And intelligent and precise preoperative evaluation and postoperative risk prediction of the antral carcinoma patient are realized.

The invention relates to a culture method of a pancreatic cancer organ model. The culture method comprises the following steps: cleaning tissues and chopping the tissues through a chopping device; transferring the chopped tissue into a centrifugal tube filled with tissue digestive juice for digestion, and collecting upper suspension and residual tissue precipitate; mixing the collected upper-layer suspension with the digested residual precipitate, and treating to obtain cell and tissue precipitates; embedding the tissues and the cells into matrigel; and after the matrigel is solidified, culturing tissue cells by using a corresponding organoid culture medium, and obtaining primary organoid tissues which are pancreatic cancer tissues. Due to the adoption of the technical scheme, the culture method of the pancreatic cancer organoid model can be used for stably culturing pancreatic cancer organoid with high success rate, and the invention also relates to a culture method of the pancreatic cancer para-carcinoma organoid model.

The invention belongs to the field of microorganisms, and particularly relates to a pleurotus citrinopileatus strain for producing ergothioneine and a preparation method and application of ergothioneine. The pleurotus citrinopileatus strain is preserved in China General Microbiological Culture Collection Center (CGMCC). According to the preparation method of the ergothioneine, lactose and casein peptone are used as a carbon source and a nitrogen source of a liquid fermentation culture medium. The pleurotus citrinopileatus strain is used for high yield of ergothioneine, and the ergothioneine produced by fermentation is used for relieving oxidative stress damage of hepatoma carcinoma cells HepG2.

An antitumor pharmaceutical composition including (i) a fluoropyrimidine, (ii) a B6 vitamer, and (iii) a folate for its use in the treatment of cancer in a subject in need thereof. The antitumor pharmaceutical composition may be for a simultaneous, separate, or sequential use for the treatment of cancer, and may be administered sequentially or concomitantly with one or more immunotherapeutic, chemotherapeutic or radiotherapeutic agent.

A method for cancer diagnosis and treatment. In particular, in identifying associations between biomedical markers which is indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular nasopharyngeal cancer (NPC) metastasis after radiation therapy. The biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably radiation therapy, wherein said biomedical marker or group of biomedical markers comprises at least 1, 2, 3, 4, or all markers selected from CXCR6, ASPHD2, DDX39B and AGAP9. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular nasopharyngeal cancer, is provided, as well as a corresponding method for classifying a subject and a medical decision support system.

The invention discloses a postoperative pathology assessment method, survival prediction method and system for esophageal cell carcinoma, and the method comprises the steps: obtaining and preprocessing WSI image data, obtaining cut small images of the WSI image data in a low-magnification view angle, a medium-magnification view angle and a high-magnification view angle, and sequentially inputting the cut small images into a selective spatial state model through feature extraction; updating the diagnosis states through a long and short term memory network, and adjusting the contribution degree of each diagnosis state through a selective memory weight; fusing all diagnosis states, and outputting the probability of tissue types through a full connection layer and a Softmax function; calculating the percentage of the residual living tumor, and obtaining a pathological assessment result according to the percentage of the residual living tumor. According to the method, the diagnosis process of doctors can be simulated, the workload of pathologists can be reduced, the evaluation consistency and universality are improved, and the survival rate can be predicted and clinical treatment decision making can be assisted through the constructed survival prediction model.

The invention provides a digestive tract cancer detection method, device and equipment, a storage medium and a program product, and relates to the technical field of image recognition. The method comprises the following steps: inputting an alimentary canal image into an image classification model to obtain an image classification result output by the image classification model; the image classification result is used for representing an identification result of cancer identification of the alimentary canal image; inputting the alimentary canal image into a semantic segmentation model to obtain a semantic segmentation result output by the semantic segmentation model; the semantic segmentation result is used for indicating whether a focus area exists in the alimentary canal image; determining a detection mode of an alimentary canal part corresponding to the alimentary canal image based on the semantic segmentation result and the image classification result; and when the detection mode indicates that the alimentary canal part corresponding to the alimentary canal image needs to be detected, outputting prompt information corresponding to the detection mode. According to the invention, high-efficiency, high-sensitivity and high-accuracy digestive tract cancer detection can be realized.

Provided are an antibody-drug conjugate and a preparation method and a use thereof, which has a structure shown in the formula Ab-[M-L-E-D] x, the drug is selected from DNA topoisomerase inhibitors, the prepared antibody-drug conjugate has a relatively good drug-antibody conjugation ratio and has excellent targeted killing effects on solid tumors such as gastric cancer, breast cancer, lung cancer, and urothelium carcinoma.

The invention belongs to the technical field of cancer resistance, and relates to a preparation method and application of curcumin-loaded composite nanoparticles. Sodium alginate and carboxymethyl chitosan chelated metal calcium ions are synthesized by adopting a liquid phase precipitation method to form double-skeleton packaged curcumin and manganese carbonate doped CuratCMCS / SA-CaCO3 / MnCO3 nanoparticles, the characteristics of poor water solubility and low bioavailability of curcumin are overcome, the drug loading rate is improved, a compact calcium shell structure also has acid responsiveness, and the drug loading capacity is improved. And the drug can be specifically disintegrated and released in an acidic tumor microenvironment. The nanoparticles show remarkable cytotoxicity to human hepatoma carcinoma cells HepG2, have a remarkable inhibition effect and can effectively induce cell apoptosis.

Presented herein are systems and methods for detecting basal-cell carcinoma (BCC) in biomedical images of skin lesions. A computing system may identify, for a first subject at risk of BCC in a first lesion on a region of an epidermis: (i) a first biomedical image of an outer layer of the region on the epidermis of the first subject acquired in accordance with dermoscopy, and (ii) a plurality of second biomedical images of at least one inner layer in the region on the epidermis of the first subject acquired in accordance with reflection confocal microscopy (RCM). The computing system may apply the first biomedical image and the plurality of second biomedical images to a model architecture. The computing system may generate, based on applying to the model architecture, a score indicating a likelihood of BCC in the first lesion.

The invention discloses a risk prediction method of endometrial carcinoma, and relates to the field of risk prediction of endometrial carcinoma, and the method comprises the steps: accessing a multi-modal data set, and building a pathological multi-modal database; analyzing the pathological multi-modal database to obtain multi-modal characteristic data; establishing a prediction model, and comparing the performance of the prediction model to obtain a comparison result; according to the risk prediction model for the endometrial carcinoma, a prediction model is selected, a pathological data set is predicted, prediction data is obtained, and the model and a pathological multi-modal database are optimized in combination with a doctor feedback result. The technical problems of lack of a multi-modal prediction model, lack of a dynamic optimization mechanism of the risk prediction model of the endometrial carcinoma and lack of image and text data support of the risk prediction model of the endometrial carcinoma in the prior art are solved.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

The utility model discloses a portable sampling device for endometrial cancer gene methylation detection in the technical field of sampling devices, which comprises an extraction cylinder, one end of the extraction cylinder is fixedly inserted with a connecting pipe, the inner wall of the connecting pipe is movably inserted with a detachable extraction pipe, and the inner wall of the detachable extraction pipe is movably inserted with a connecting pipe. A plurality of guide blocks are fixedly arranged on the outer wall of the end, inserted into the connecting pipe, of the detachable extraction pipe, the guide blocks are in sliding fit with the inner wall of the connecting pipe, and two toothed plate sealing pieces used for blocking the connecting pipe are movably arranged on the inner wall of the extraction cylinder; after the device is used, the grab handle is firstly detached, then the detachable extraction pipe is detached, and at the moment, the guide block slides along the inner wall of the connecting pipe, so that the connecting pipe drives the transmission gear to rotate reversely, and the two toothed plate sealing pieces are reset along with the reverse rotation of the transmission gear to seal the connecting pipe; therefore, the possibility that external sundries enter the extraction barrel through the connecting pipe when the device is not used is reduced.

The present invention provides sequencing independent quantitative methylation profiling compositions, epigenetic biomarker primers, epigenetic biomarker probes, multiplex compositions, kit, and uses thereof for (i) quantifying and assessing the levels and patterns of epigenetic methylation to predict the risk of developing cancer and specifically, to predict the risk of developing carcinomas marked by epigenetic aberrations or (ii) to detect the presence or absence of cancer and specifically, to detect the presence or absence of carcinomas marked by epigenetic aberrations or (iii) combination thereof.

The forklift hood surface treatment equipment comprises a base, a box door, a stepping motor, a machining box and a containing box, the containing box is fixedly connected to the left side of the top of the base, and the machining box is fixedly connected to the top of the machining box. By arranging the controller, the controller extracts harmful gas through the extraction mechanism and then filters the harmful gas through the filtering assembly, so that the effect of filtering the harmful gas is achieved, and the problem that the device can generate the harmful gas in the paint spraying operation, so that the paint spraying efficiency is improved is solved. The spray paint waste gas is not provided with a structure for extracting and filtering harmful gas, the harmful gas can be exposed outside, symptoms such as respiratory tract stimulation, dyspnea, cough and asthma can be caused by long-term inhalation of the spray paint waste gas containing the organic solvent and the harmful gas, and the risk of cancer can be increased by long-term contact with harmful substances such as formaldehyde and benzene in the spray paint. Especially nasopharyngeal carcinoma, laryngeal carcinoma and the like, so that certain harm to a human body is caused.

A method of treating cancer involves administering a combination of activators comprising a therapeutically effective dose of acylfluben or a pharmaceutically acceptable salt thereof and a therapeutically effective dose of an anti-CD20 antibody. The anti-CD20 antibody can be selected from rituximab, obinutuzumab, ofatumumab, and tocitumomab. The cancer may be a B-cell carcinoma.

The invention discloses an angiopoietin detection method and device, electronic equipment and a storage medium, and relates to the technical field of image processing, and the method comprises the steps: obtaining hematoxylin-eosin staining pathological images of different hepatocellular carcinoma patient tissues; segmenting cancer tissue areas in each pathological image, and randomly selecting the cancer tissue areas as sub-images; extracting a plurality of features of each sub-image, and screening the features to obtain an optimal feature subset; constructing a pathological omics model based on the optimal feature subset; and calculating the angiopoietin expression probability of the tissue of the corresponding hepatocellular carcinoma patient according to the characteristics by using a pathomics model, and detecting the expression level of the angiopoietin according to the angiopoietin expression probability. According to the method, the rich features of the pathological image are obtained, then the pathological omics model is constructed, the corresponding angiopoietin expression probability is predicted for each feature, the expression level of the angiopoietin can be objectively and truly detected based on the pathological image, and the detection accuracy of the angiopoietin is improved.

The present invention proposes the inhibition of the catalytic function of the SWI / SNF complex in patients with NUT carcinoma, to promote the differentiation and specific death of tumour cells. Specifically, inhibitors of the activity of the SMARCA4 and / or SMARCA2 catalytic subunits of the SWI / SNF complex, for the use thereof in the treatment of NUT carcinoma, are described.

The invention provides an intrahepatic cholangiocarcinoma organ culture medium and a culture method. The culture medium is prepared from the following components according to final concentration: 0.5 to 200 mu M of A83-01, 0.1 to 100 mu M of EGF (Epidermal Growth Factor), 10 to 500 ng / ml of FGF10 (Fibroblast Growth Factor), 1 to 200 ng / ml of HGF (Hepatitis Growth Factor), 0.5 to 200 mu M of Forskolin, 0.01 to 20 mu M of Gastrin I, 0.5 to 100 mM of Nicotinamide, 1 to 500 mu M of Y-27632, 0.5 to 100 nM of dexamethasone and 20 to 500 mu g / ml of primary cell antibiotics. All the components are dissolved in a DMEM / F12 culture solution. When the culture medium is used for culturing the intrahepatic cholangiocellular carcinoma organoid, the rapid amplification of the intrahepatic cholangiocellular carcinoma stem cells and the maturation and differentiation of the organoid are facilitated, the passage times are obviously increased, and the same tissue structure and genome characteristics of primary tissues can still be maintained after multiple passages.

The invention discloses a pre-diagnosis information processing system based on large model intrahepatic bile duct stone cancerization, which belongs to the field of intrahepatic bile duct stone cancerization, and comprises a data acquisition module for acquiring character data of a patient to form a structured data packet, and a pre-diagnosis information processing module for processing pre-diagnosis information based on an unstructured text input to the patient, the NLP analysis module is used for establishing a sequential clinical basic file and is used for collecting multi-source data of a patient; the multi-modal receiving module is used for forming a complete file in combination with a clinical basic file; the intelligent diagnosis and analysis module is used for receiving the complete file and performing sequential analysis; the grading and decision-making module is used for automatically matching preset action suggestions according to parameters output by the intelligent diagnosis and analysis module; the multimodal data is fused, the dynamic time sequence analysis function is performed, and the pre-diagnosis function focuses on pre-diagnosis of intrahepatic bile duct stone cancerization.

The present invention relates to an antibody or fragment thereof specifically binding to meningeosis carcinoma-specific antigen, such as DDX53, KIF3C, and AKR1A1, an anti-body or fragment thereof for use in the prophylaxis and / or treatment of cancer, preferably melanoma, further preferably melanoma with leptomeningeal spread, highly preferably melanoma with meningeosis carcinomatosa, a pharmaceutical composition comprising said antibody or fragment thereof, a nucleic acid encoding said antibody or fragment thereof, a vector comprising said nucleic acid, a prokaryotic or eukaryotic host cell comprising said vector, and to a method for the prophylaxis and / or treatment of cancer, preferably melanoma, further preferably melanoma with leptomeningeal spread, highly preferably melanoma with meningeosis carcinomatosa, in a living being, comprising the admin- istration of a prophylactically and / or therapeutically effective amount of said antibody or fragment thereof or said pharmaceutical composition.

The invention discloses an application of a DHCR7 inhibitor in enhancing the drug sensitivity of mitartan. The DHCR7 gene related to the adrenal cortical carcinoma is obtained through machine learning screening, cell experiments verify that knock-down of the DHCR7 can enhance the sensitivity of a subject to mitartan, and a new research strategy and a treatment target are provided for treatment of the adrenal cortical carcinoma.